Our Solutions

Gain strategic, in-depth insights across your product’s lifecycle.

MMS is the trusted, data-focused clinical research organization (CRO) chosen by Sponsors across the globe for our dedication to providing comprehensive, integrated solutions in all aspects of drug development. Our expertise spans regulatory submissions support from pre-IND to marketing authorization, comprehensive safety solutions, full-service biometrics management and execution, and functional service provider (FSP) models, with a deep bench of therapeutic area expertise.

We believe in delivering strategic, in-depth insights which focus on the long-term success of our customers and their assets. This holistic approach ensures that every aspect of your drug development process is meticulously managed, from initial IND submissions through to marketing authorization approvals and post-approval activities. What sets MMS apart is our unwavering focus on data-driven methodologies and a commitment to delivering tailored, end-to-end solutions that are necessary to drive your programs and projects to success. The result is successful outcomes for our customers and the best customer satisfaction and employee stability in the industry.

Explore our solutions to see how MMS can help you achieve your drug development goals with confidence and precision.

Suggested For You

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

regulatory intelligence

August 27th, 2024

Recent Guidance on Diversity Action Planning

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Take Reflections on the Recent Donanemab Approval

webinar

September 12th, 2024

No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology

regulatory intelligence

August 9th, 2024

FDA Updates 2024 Language Access Plan

regulatory intelligence

August 3rd, 2024

EMA Launches New Pilot Program for Orphan Medical Devices

perspectives

July 30th, 2024

The Critical Role of Quality Control (QC) – Medical Writing and Beyond

regulatory intelligence

July 26th, 2024

Key Decision Points for Recent Oncology Approvals

regulatory intelligence

July 24th, 2024

Comments Open for Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products

perspectives

July 23rd, 2024

PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma

news

July 17th, 2024

Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization